Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.

Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.

Key Figures

TD Cowen conference date: March 3, 2026 TD Cowen presentation time: 3:10 pm ET Leerink conference date: March 9, 2026 +5 more

8 metrics

TD Cowen conference date March 3, 2026 TD Cowen 46th Annual Health Care Conference presentation date

TD Cowen presentation time 3:10 pm ET Spyre presentation and fireside time at TD Cowen conference

Leerink conference date March 9, 2026 Leerink Global Healthcare Conference fireside chat date

Leerink fireside time 8:40 am ET Spyre fireside time at Leerink Global Healthcare Conference

Jefferies summit date March 10, 2026 Jefferies Biotech on the Beach Summit participation date

Number of March events 3 conferences Total investor conferences listed in March 2026

TD Cowen edition 46th annual Edition of TD Cowen Health Care Conference

Price move pre-news 2.24% SYRE 24h price change ahead of this conference announcement

Market Reality Check

Price: $43.45 Vol: Volume 1,095,218 vs 20-da...

high vol

$43.45 Last Close

Volume Volume 1,095,218 vs 20-day avg 722,989 (relative 1.51x) indicates elevated trading into the conference schedule. high

Technical Shares at $44.18 trade above the $22.36 200-day MA and about 3.45% below the $45.76 52-week high.

Peers on Argus

SYRE gained 2.24% with mixed peer moves: ABUS up 4.52%, RAPP up 1.07%, URGN up 0...

SYRE gained 2.24% with mixed peer moves: ABUS up 4.52%, RAPP up 1.07%, URGN up 0.63%, while UPB and VERV were modestly negative, pointing to stock-specific strength rather than a broad biotech move.

Common Catalyst Several biotech peers (e.g., URGN, RAPP) also issued conference-participation announcements, highlighting an investor conference season theme rather than a company-specific data catalyst.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Earnings and update	Positive	+1.6%	Reported 2025 results, strong cash runway and multiple 2026 proof-of-concept readouts.
Feb 18	Scientific presentations	Positive	+1.8%	ECCO data on SPY003, SKYLINE trial and superior dual-targeting preclinical results.
Feb 06	Inducement awards	Neutral	-3.3%	Granted 30,200 inducement stock options to new employees under equity plan.
Jan 23	Inducement award CCO	Neutral	+0.8%	Equity inducement grant for newly appointed Chief Commercial Officer under 2018 plan.
Jan 12	2026 outlook	Positive	+7.2%	Outlined six 2026 POC readouts and cash balance expected to fund into H2 2028.

Pattern Detected

Recent news tied to pipeline progress, strategy, and financial strength has generally been met with positive price reactions, while administrative equity grants saw the only notable pullback.

Recent Company History

Over the last months, Spyre highlighted a transformational 2026 with six planned proof-of-concept readouts and reported strong cash resources, including $756.5M at year-end 2025 and an October 2025 raise. Scientific visibility increased via ECCO presentations on SPY003 and the SKYLINE platform. Administrative items such as inducement option grants produced mixed, mostly modest reactions. Against this backdrop, today’s March investor-conference participation fits a pattern of active investor and scientific engagement layered on top of a well-funded, data-rich 2026 plan.

Regulatory & Risk Context

Active S-3 Shelf · $500,000,000

Shelf Active

Active S-3 Shelf Registration 2026-02-19

$500,000,000 registered capacity

An effective S-3 shelf filed on February 19, 2026 permits Spyre to offer up to $500,000,000 of various securities, including an ATM facility of up to $154,059,875, providing flexible capital-raising capacity for working capital, R&D, in-licensing, acquisitions, and other corporate uses.

Market Pulse Summary

This announcement highlights Spyre’s participation in three March healthcare conferences, with sched...

Analysis

This announcement highlights Spyre’s participation in three March healthcare conferences, with scheduled presentations and fireside discussions that increase investor visibility. Against a backdrop of shares trading near their 52-week high and above the 200-day MA, the news adds to an already active cadence of scientific and corporate updates. Investors may watch for commentary from these events alongside upcoming proof-of-concept readouts and monitor how conference messaging aligns with the company’s previously disclosed 2026 development and financing plans.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026

Members of the Spyre management team will host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

FAQ

When will Spyre Therapeutics (SYRE) present at the TD Cowen 46th Annual Health Care Conference?

Spyre will present on Tuesday, March 3, 2026 at 3:10 PM ET. According to the company, management will attend the TD Cowen conference in Boston and offer a live audio webcast and replay on its investor events site.

What are the dates and times for Spyre Therapeutics (SYRE) investor events in Miami in March 2026?

Spyre is scheduled for Leerink on March 9, 2026 at 8:40 AM ET and Jefferies on March 10, 2026. According to the company, management will hold fireside and one-on-one meetings with webcasts available online.

Will Spyre Therapeutics (SYRE) provide webcasts or replays of the March 2026 conference presentations?

Yes. Live audio webcasts and replays will be available on the company's investor events website. According to the company, investors can access recordings and related presentation materials via the IR events page.

Can investors schedule one-on-one meetings with Spyre Therapeutics (SYRE) management during the March 2026 conferences?

Yes. Members of Spyre management will host one-on-one investor meetings during the conferences. According to the company, these meetings are planned alongside scheduled fireside sessions and conference presentations.

Where can investors find details for Spyre Therapeutics (SYRE) conference presentations in March 2026?

Conference presentation details and webcast links will be posted on the Spyre investor events webpage. According to the company, the IR events page will host times, replay links, and related presentation materials.